JINGHAO MEDICAL
872925
TONGYI AEROSPACE
871642
Jiangsu Olive Sensors High-Tech
300507
4
Jing-Jin Electric Technologies
688280
5
SHENGNAN TECHNOLOGY
837006
US Stock MarketDetailed Quotes
ERNA Eterna Therapeutics
- 0.2080
- +0.0100+5.05%
Close May 6 16:00 ET
- 0.2000
- -0.0080-3.85%
Post 20:01 ET
12.93MMarket Cap-0.06P/E (TTM)
0.2100High0.1980Low55.50KVolume0.2000Open0.1980Pre Close11.36KTurnover0.27%Turnover RatioLossP/E (Static)62.18MShares2.625052wk High7.70P/B4.28MFloat Cap0.150652wk Low--Dividend TTM20.56MShs Float1613.4000Historical High--Div YieldTTM6.06%Amplitude0.1506Historical Low0.2040Avg Price1Lot Size
Eterna Therapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 755.88%582K | -94.12%1K | 854.90%487K | 47K | 47K | 68K | 17K | 51K | 0 | 0 |
| Operating revenue | 755.88%582K | -94.12%1K | 854.90%487K | --47K | --47K | --68K | --17K | --51K | --0 | --0 |
| Cost of revenue | -59.32%96K | 0 | -150.00%-60K | 95K | 22.00%61K | 236K | 66K | 120K | 0 | 50K |
| Gross profit | 389.29%486K | 102.04%1K | 892.75%547K | -48K | 72.00%-14K | -168K | -49K | -69K | 0 | -50K |
| Operating expense | -13.51%17.74M | -52.80%2.7M | -19.39%4.38M | 19.42%4.88M | 9.63%5.77M | -23.90%20.51M | 0.99%5.72M | -34.54%5.44M | -42.55%4.09M | -16.36%5.27M |
| Selling and administrative expenses | -9.97%13.13M | -64.65%1.54M | -16.50%3.38M | 50.42%3.9M | 20.13%4.32M | -11.89%14.59M | 17.79%4.36M | 21.19%4.05M | -52.33%2.59M | -20.43%3.59M |
| -General and administrative expense | -9.97%13.13M | -64.65%1.54M | -16.50%3.38M | 50.42%3.9M | 20.13%4.32M | -11.89%14.59M | 17.79%4.36M | 21.19%4.05M | -52.33%2.59M | -20.43%3.59M |
| Research and development costs | -22.23%4.6M | -14.85%1.16M | -27.83%1M | -34.16%987K | -12.90%1.46M | -43.03%5.92M | -30.68%1.36M | -72.05%1.39M | -11.04%1.5M | -6.06%1.67M |
| Operating profit | 16.57%-17.25M | 53.22%-2.7M | 30.34%-3.84M | -20.59%-4.93M | -8.86%-5.79M | 23.28%-20.68M | -1.86%-5.77M | 33.71%-5.51M | 42.55%-4.09M | 15.57%-5.32M |
| Net non-operating interest income expense | -1,266.18%-6.5M | -733.51%-3.23M | -1,392.04%-1.69M | -3,420.83%-797K | -78,700.00%-786K | -1,486.67%-476K | -6,366.67%-388K | -1,030.00%-113K | 284.62%24K | 200.00%1K |
| Non-operating interest income | 80.43%249K | ---- | ---- | ---- | ---- | --138K | ---- | ---- | --24K | --1K |
| Non-operating interest expense | 999.67%6.75M | 562.17%3.48M | 1,392.04%1.69M | --797K | --786K | 1,946.67%614K | 8,666.67%526K | 1,030.00%113K | ---- | ---- |
| Other net income (expense) | -3,891.54%-20.76M | 4,675.00%183K | -111,000.00%-21.07M | 146.01%202K | 27.08%-70K | -121.29%-520K | -100.33%-4K | -98.11%19K | -111.76%-439K | 96.88%-96K |
| Gain on sale of security | -769.87%-1.05M | -1,944.90%-904K | -1,135.00%-207K | -25.68%136K | -55.56%-70K | -98.42%156K | -83.28%49K | -98.01%20K | -98.26%183K | 97.68%-45K |
| Earnings from equity interest | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | ---51K |
| Special income (charges) | -5,981.29%-20.8M | --0 | ---20.86M | 119.30%66K | ---- | 94.55%-342K | --0 | --0 | 94.94%-342K | ---- |
| -Less：Restructuring and merger&acquisition | 44.07%-66K | --0 | --0 | 44.07%-66K | ---- | ---118K | --0 | --0 | ---118K | ---- |
| -Less:Other special charges | 4,435.65%20.86M | --0 | --20.86M | ---- | ---- | --460K | --0 | ---- | --460K | ---- |
| Other non- operating income (expenses) | 425.45%1.09M | ---- | ---- | ---- | ---- | 70.73%-334K | -5,400.00%-53K | ---1K | -27,900.00%-280K | ---- |
| Income before tax | -105.39%-44.51M | 6.64%-5.75M | -374.94%-26.59M | -22.69%-5.53M | -22.77%-6.64M | 11.67%-21.67M | -38.39%-6.16M | 23.42%-5.6M | -32.55%-4.5M | 42.28%-5.41M |
| Income tax | 1,100.00%30K | 375.00%11K | 250.00%12K | -25.00%3K | -20.00%4K | -106.67%-3K | -110.00%-4K | -260.00%-8K | 4K | 5K |
| Net income | -105.55%-44.54M | 6.40%-5.76M | -375.84%-26.6M | -22.65%-5.53M | -22.73%-6.65M | 11.84%-21.67M | -37.07%-6.15M | 23.58%-5.59M | -32.67%-4.51M | 42.23%-5.42M |
| Net income continuous Operations | -105.55%-44.54M | 6.40%-5.76M | -375.84%-26.6M | -22.65%-5.53M | -22.73%-6.65M | 11.84%-21.67M | -37.07%-6.15M | 23.58%-5.59M | -32.67%-4.51M | 42.23%-5.42M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | -105.55%-44.54M | 6.40%-5.76M | -375.84%-26.6M | -22.65%-5.53M | -22.73%-6.65M | 11.84%-21.67M | -37.07%-6.15M | 23.58%-5.59M | -32.67%-4.51M | 42.23%-5.42M |
| Preferred stock dividends | 0.00%16K | 0.00%8K | 0.00%8K | 0.00%16K | 0.00%8K | 0.00%8K | ||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | -105.47%-44.56M | 6.40%-5.77M | -375.84%-26.6M | -22.61%-5.54M | -22.73%-6.65M | 11.84%-21.68M | -37.00%-6.16M | 23.58%-5.59M | -32.59%-4.52M | 42.23%-5.42M |
| Basic earnings per share | 20.10%-3.26 | 90.16%-0.1122 | -377.67%-4.92 | -20.00%-1.02 | -16.04%-1.23 | 49.38%-4.08 | 8.06%-1.14 | 58.63%-1.03 | 26.72%-0.85 | 69.71%-1.06 |
| Diluted earnings per share | 20.10%-3.26 | 90.16%-0.1122 | -377.67%-4.92 | -20.00%-1.02 | -16.04%-1.23 | 49.38%-4.08 | 8.06%-1.14 | 58.63%-1.03 | 26.72%-0.85 | 69.71%-1.06 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- |
Market Insights
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀